Chemours [CC] vs Linde plc [LIN] Detailed Stock Comparison
Chemours
NYSE
Loading...
Linde plc
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Chemours wins in 5 metrics, Linde plc wins in 15 metrics, with 0 ties. Linde plc appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemours | Linde plc | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 67.83 | 34.37 | Linde plc |
| Price-to-Book Ratio | 9.24 | 5.86 | Linde plc |
| Debt-to-Equity Ratio | 1,845.61 | 60.56 | Linde plc |
| PEG Ratio | -0.11 | 27.90 | Chemours |
| EV/EBITDA | 9.19 | 18.94 | Chemours |
| Profit Margin (TTM) | -7.04% | 20.02% | Linde plc |
| Operating Margin (TTM) | 4.46% | 28.29% | Linde plc |
| EBITDA Margin (TTM) | 4.46% | 28.29% | Linde plc |
| Return on Equity | -85.27% | 17.01% | Linde plc |
| Return on Assets (TTM) | 2.98% | 6.96% | Linde plc |
| Free Cash Flow (TTM) | $-993.00M | $4.93B | Linde plc |
| Dividend Yield | 6.82% | 1.58% | Chemours |
| 1-Year Return | -26.68% | 3.21% | Linde plc |
| Price-to-Sales Ratio (TTM) | 0.37 | 6.74 | Chemours |
| Enterprise Value | $6.10B | $242.90B | Linde plc |
| EV/Revenue Ratio | 1.04 | 7.36 | Chemours |
| Gross Profit Margin (TTM) | 17.21% | 48.75% | Linde plc |
| Revenue per Share (TTM) | $39 | $69 | Linde plc |
| Earnings per Share (Diluted) | $-2.74 | $13.76 | Linde plc |
| Beta (Stock Volatility) | 1.59 | 0.97 | Linde plc |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Chemours vs Linde plc Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemours | 8.69% | -6.10% | 4.27% | 34.25% | -15.57% | -15.32% |
| Linde plc | 0.20% | 0.64% | 2.19% | 5.53% | 4.96% | 16.07% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemours | -26.68% | -60.43% | -32.52% | 46.18% | -32.13% | -32.13% |
| Linde plc | 3.21% | 67.93% | 89.58% | 352.69% | 450.77% | 892.79% |
Performance & Financial Health Analysis: Chemours vs Linde plc
| Metric | CC | LIN |
|---|---|---|
| Market Information | ||
| Market Cap | $2.19B | $222.60B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 5,368,710 | 1,460,950 |
| 90 Day Avg. Volume | 4,430,493 | 1,675,487 |
| Last Close | $15.38 | $481.67 |
| 52 Week Range | $9.13 - $22.38 | $408.65 - $487.49 |
| % from 52W High | -31.28% | -1.19% |
| All-Time High | $58.08 (Oct 23, 2017) | $487.49 (Oct 14, 2024) |
| % from All-Time High | -73.52% | -1.19% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.00% |
| Quarterly Earnings Growth | 0.05% | 0.03% |
| Financial Health | ||
| Profit Margin (TTM) | -0.07% | 0.20% |
| Operating Margin (TTM) | 0.04% | 0.28% |
| Return on Equity (TTM) | -0.85% | 0.17% |
| Debt to Equity (MRQ) | 1,845.61 | 60.56 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.58 | $80.70 |
| Cash per Share (MRQ) | $3.35 | $11.23 |
| Operating Cash Flow (TTM) | $258.00M | $9.63B |
| Levered Free Cash Flow (TTM) | $99.25M | $3.41B |
| Dividends | ||
| Last 12-Month Dividend Yield | 6.82% | 1.58% |
| Last 12-Month Dividend | $0.75 | $7.28 |
Valuation & Enterprise Metrics Analysis: Chemours vs Linde plc
| Metric | CC | LIN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 67.83 | 34.37 |
| Forward P/E | 6.33 | 27.90 |
| PEG Ratio | -0.11 | 27.90 |
| Price to Sales (TTM) | 0.37 | 6.74 |
| Price to Book (MRQ) | 9.24 | 5.86 |
| Market Capitalization | ||
| Market Capitalization | $2.19B | $222.60B |
| Enterprise Value | $6.10B | $242.90B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.04 | 7.36 |
| Enterprise to EBITDA | 9.19 | 18.94 |
| Risk & Other Metrics | ||
| Beta | 1.59 | 0.97 |
| Book Value per Share (MRQ) | $1.58 | $80.70 |
Financial Statements Comparison: Chemours vs Linde plc
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CC | LIN |
|---|---|---|
| Revenue/Sales | $1.37B | $8.11B |
| Cost of Goods Sold | $1.13B | $4.16B |
| Gross Profit | $236.00M | $3.96B |
| Research & Development | $27.00M | $38.00M |
| Operating Income (EBIT) | $78.00M | $2.22B |
| EBITDA | $181.00M | $3.15B |
| Pre-Tax Income | $0 | $2.18B |
| Income Tax | $4.00M | $511.00M |
| Net Income (Profit) | $-4.00M | $1.71B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CC | LIN |
|---|---|---|
| Cash & Equivalents | $464.00M | $5.29B |
| Total Current Assets | $2.93B | $13.60B |
| Total Current Liabilities | $1.67B | $14.49B |
| Long-Term Debt | $4.28B | $17.61B |
| Total Shareholders Equity | $580.00M | $39.46B |
| Retained Earnings | $1.66B | $13.55B |
| Property, Plant & Equipment | $8.30B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CC | LIN |
|---|---|---|
| Operating Cash Flow | $-104.00M | $2.34B |
| Capital Expenditures | $-84.00M | N/A |
| Free Cash Flow | $-196.00M | $891.00M |
| Debt Repayment | $-46.00M | $-1.01B |
| Common Stock Repurchase | N/A | $-1.11B |
Short Interest & Institutional Ownership Analysis
| Metric | CC | LIN |
|---|---|---|
| Shares Short | 14.87M | 5.14M |
| Short Ratio | 3.67 | 2.93 |
| Short % of Float | 0.15% | 0.01% |
| Average Daily Volume (10 Day) | 5,368,710 | 1,460,950 |
| Average Daily Volume (90 Day) | 4,430,493 | 1,675,487 |
| Shares Outstanding | 149.43M | 473.24M |
| Float Shares | 141.48M | 469.47M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 1.01% | 0.88% |
Dividend Analysis & Yield Comparison: Chemours vs Linde plc
| Metric | CC | LIN |
|---|---|---|
| Last 12-Month Dividend | $0.75 | $7.28 |
| Last 12-Month Dividend Yield | 6.82% | 1.58% |
| 3-Year Avg Annual Dividend | $0.83 | $5.83 |
| 3-Year Avg Dividend Yield | 1.03% | 0.34% |
| 3-Year Total Dividends | $2.50 | $17.48 |
| Ex-Dividend Date | Feb 28, 2025 | Sep 04, 2025 |